Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)

被引：0
|
作者：
Pemmaraju, Naveen [1 ]
Kantarjian, Hagop [2 ]
Shan, Jianqin [2 ]
Jabbour, Elias [2 ]
Quintas-Cardama, Alfonso
Verstovsek, Srdan
Ravandi, Farhad
Wierda, William G. [2 ]
O'Brien, Susan [2 ]
Cortes, Jorge E. [2 ]
机构：
[1] MD Anderson, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：527 / 528
页数：2
相关论文
共 50 条
  • [41] Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI)
    Nazha, Aziz
    Williams, Loretta A.
    Kantarjian, Hagop M.
    Ault, Patricia S.
    Garcia-Gonzalez, Araceli
    Williams, Janet L.
    Probst, Alexandra
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Shi, Quiling
    Cleeland, Charles S.
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1617 - 1617
  • [42] IMPACT OF NILOTINIB REIMBURSEMENT COVERAGE ON THE USE OF TYROSINE KINASE INHIBITORS (TKI) FOR CHRONIC MYELOID LEUKEMIA (CML) IN CHINESE TERTIARY CARE HOSPITALS: A RETROSPECTIVE ANALYSIS
    Zhang, Y.
    Chen, W.
    Xu, Y.
    Pathak, A.
    Lu, Y.
    Yang, D.
    Zhai, Y.
    VALUE IN HEALTH, 2022, 25 (07) : S474 - S474
  • [43] Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML)
    Santos, Fabio P. S.
    Kantarjian, Hagop
    Fava, Carmen
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Komblau, Steven
    Ravandi, Farhad
    Wierda, William
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1104 - 1104
  • [44] The effect of interleukin-11 (Oprelvekin, Neumega®) on thrombocytopenia associated with tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML).
    Aribi, Ahmed M.
    Kantarjian, Hagop
    Ault, Patricia
    Koller, Charles Asa
    Thomas, Deborah
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 609A - 609A
  • [45] A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).
    Guilhot, Francois
    Coombs, John
    Zernovak, Oleg
    Szczudlo, Tomasz
    Rosti, Gianantonio
    BLOOD, 2010, 116 (21) : 644 - 644
  • [46] Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP)
    Naqvi, Kiran
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    Jabbour, Elias
    O'Brien, Susan
    Burton, Elizabeth M.
    Verstovsek, Srdan
    Ravandi, Farhad
    Wierda, William G.
    Borthakur, Gautam
    Quintas-Cardama, Alfonso
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1616 - 1617
  • [47] Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Kristin M. Phillips
    Javier Pinilla-Ibarz
    Eduardo Sotomayor
    Morgan R. Lee
    Heather S. L. Jim
    Brent J. Small
    Lubomir Sokol
    Jeffrey Lancet
    Sara Tinsley
    Kendra Sweet
    Rami Komrokji
    Paul B. Jacobsen
    Supportive Care in Cancer, 2013, 21 : 1097 - 1103
  • [48] An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies
    Guilhot, Francois
    Coombs, John
    Szczudlo, Tomasz
    Zernovak, Oleg
    Macdonald, Nancy J.
    Shapiro, Ari
    BLOOD, 2010, 116 (21) : 176 - 177
  • [49] Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Phillips, Kristin M.
    Pinilla-Ibarz, Javier
    Sotomayor, Eduardo
    Lee, Morgan R.
    Jim, Heather S. L.
    Small, Brent J.
    Sokol, Lubomir
    Lancet, Jeffrey
    Tinsley, Sara
    Sweet, Kendra
    Komrokji, Rami
    Jacobsen, Paul B.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (04) : 1097 - 1103
  • [50] Pulmonary Adverse Effects Associated with Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia (CML)
    Ali, Naveed
    Durrani, Jibran
    Naglak, Mary
    Berman, Jessica
    Auerbach, Herbert Edward
    Pickens, Peter V.
    BLOOD, 2017, 130
12345